Serratiopeptidase + Diclofenac Potassium + ParacetamolThird Party Manufacturing in India

Serratiopeptidase + Diclofenac Potassium + Paracetamol combines three pharmacologically distinct agents to deliver comprehensive pain relief, inflammation control, and antipyresis through complementary mechanisms of action.

Diclofenac Potassium potently inhibits cyclooxygenase-1 and cyclooxygenase-2, blocking the conversion of arachidonic acid into prostaglandin H₂ and subsequently reducing the synthesis of prostaglandins, prostacyclin, and thromboxanes at peripheral tissue sites. This inhibition decreases vasodilation, vascular permeability, oedema, and the sensitisation of peripheral nociceptors, providing robust anti-inflammatory and analgesic effects. The potassium salt ensures rapid absorption and quick onset of action, which is essential for acute pain management.

Paracetamol acts through a distinct central mechanism, primarily inhibiting cyclooxygenase-3 in the hypothalamus and modulating descending serotonergic pain pathways. It raises the pain threshold and provides antipyretic activity by acting on the hypothalamic heat-regulating centre. Paracetamol lacks significant peripheral anti-inflammatory activity but complements the diclofenac action by targeting the central component of pain perception.

Serratiopeptidase is a zinc-metalloprotease that dissolves fibrin barriers, thins inflammatory exudates, and improves microcirculation at the injury site. It accelerates the clearance of oedema fluid and devitalised tissue while suppressing bradykinin and pro-inflammatory cytokine release. The triple combination covers peripheral inflammation, central pain signalling, and tissue-level fluid accumulation simultaneously.

Therapeutic Uses

Serratiopeptidase + Diclofenac Potassium + Paracetamol is prescribed for:

• Acute Severe Pain with Inflammation: First-line therapy for conditions where pain is accompanied by significant swelling, such as acute gout flares, severe dental pain, and traumatic musculoskeletal injuries.
• Post-Surgical Pain and Oedema: Used extensively after orthopaedic, dental, and general surgical procedures to manage both the inflammatory response and the post-operative pain.
• Fever with Body Ache: Effective for febrile conditions accompanied by myalgia and arthralgia, such as viral fevers and dengue-associated musculoskeletal pain.
• Osteoarthritis and Rheumatoid Arthritis Exacerbations: Provides relief during acute flare-ups when both inflammation and pain intensity are high.
• Ear, Nose and Throat Infections: Used in severe sinusitis, tonsillitis, and otitis media where infection-related inflammation and pain require multi-mechanism coverage.
• Dysmenorrhoea: Prescribed for severe menstrual cramps where both prostaglandin-mediated uterine contraction pain and systemic inflammation contribute to discomfort.

Why Manufacturers Choose Serratiopeptidase + Diclofenac Potassium + Paracetamol

This triple combination is one of the highest-prescribed analgesic formulations in the Indian pharmaceutical market. Its multi-mechanism coverage means it is rarely substituted by generic monotherapies, ensuring strong brand loyalty and repeat prescriptions for PCD franchise partners. The combination is manufactured in high volumes across India, with established supply chains for all three active pharmaceutical ingredients. The paracetamol component is one of the most cost-effective APIs in the market, helping manufacturers achieve competitive pricing while maintaining healthy margins on the premium diclofenac and serratiopeptidase components. Export demand is particularly strong from African and Southeast Asian markets where multi-ingredient analgesic tablets are preferred over single-agent products.

This makes Serratiopeptidase + Diclofenac Potassium + Paracetamol one of the most commercially viable combination products for third party manufacturing in India, with unmatched prescription volume across all seasons.